Pneumococcal polysaccharide vaccine
PCV13 vaccine under development for phase-3 clinical test can satisfy deficient market demands in China. As compared with similar products in the market, this product has manifested its superior advantages according to preliminary clinical research. PCV20 under development is expected to be the first 20v pneumococcal polysaccharide vaccine in China. PPSV23 vaccine under development also has a high market potential, which can be offered to people of different ages and income in together with PCV13 and PCV20 owing to its coupling availability.